New drugs are coming: the latest price and efficacy of selinesol in 2024

Selinexor (Selinexor) is a new type of nuclear protein transport inhibitor, mainly used to treat refractory or relapsed multiple myeloma (Multiple Myeloma, MM), especially for patients who have received multiple treatments but the disease still progresses. The following will discuss the efficacy of selinesol based on clinical experimental data.

1. Clinical trial background: Clinical trials of selinesol mainly include trials targeting different stages and patient groups of multiple myeloma. Some of the trials are focused on its efficacy in refractory or relapsed multiple myeloma, while others are looking at selinesol in combination with other drugs.

2. Efficacy in refractory or relapsed multiple myeloma: Some clinical trial data show that selinesol has a certain efficacy in patients with refractory or relapsed multiple myeloma. This efficacy is mainly reflected in patients who have poor response to previous treatment regimens and disease progression.

3. ORR and PFSIndicators: Commonly used evaluation indicators in clinical trials include overall response rate (Overall Response Rate, ORR) and progression-free survival (Progression-Free Survival, PFS). ORR refers to the proportion of patients who achieve complete or partial remission during treatment, while PFS refers to the time from the start of treatment to disease progression.

4. Clinical trial results: One of the pivotal clinical trials for selinexor is the STORM (Selinexor Treatment of Refractory Myeloma) study, which focuses on patients with refractory or relapsed multiple myeloma. According to the study results, selinesol showed certain efficacy in this patient group, with its ORR reaching a certain level and PFS also improving. These data suggest that selinesol may provide an effective treatment option for patients with refractory or relapsed multiple myeloma.

5. Different treatment combinations of selinesol: In addition to monotherapy, selinesol has also been included in some studies of combination treatment regimens, with other anti-cancer drugs such as albumin-bound atuximab (daratumumab). These combination treatment options are designed to increase the overall efficacy of treatment, especially in terms of improving overall patient survival.

6. Side Effects and Safety: However, treatment with selinesol is not without side effects. Some patients may experience adverse effects such as fatigue, nausea, and anemia while taking selinesol. In clinical trial data, researchers also evaluated the safety of selinesol to ensure that patients can safely tolerate the drug while receiving treatment.

7. Personalized treatment: Overall, selinexol has shown certain efficacy as a new drug for the treatment of refractory or relapsed multiple myeloma. However, individual differences and disease characteristics will affect a patient's response to selinesol, so the treatment process requires doctors to make individual adjustments based on the patient's specific conditions.

8. Follow-up research and progress: As time goes by, research and practical experience on Seleniso will continue to accumulate. Further clinical trials and follow-up studies will provide us with a more comprehensive and in-depth understanding to better guide the application of selinesol in the treatment of multiple myeloma.

Taken together, selinesol has shown certain efficacy in the treatment of refractory or relapsed multiple myeloma, but patients should understand their doctor's recommendations in detail before use, including possible side effects and treatment effects, to make informed decisions. In addition, because research data may change over time, patients and physicians should pay attention to the latest clinical research developments when making decisions.

Seleniso is already on the market in China and has been included in medical insurance, but its price is quite expensive, about 10,000 to 20,000 yuan, making patients bear higher treatment costs. It is recommended to consult the local hospital pharmacy for specific prices and medical insurance reimbursement status. Different from the domestic market, Seleniso has two options: original drug and generic drug in the foreign market. The original drug is the American version of the original drug. Because of its higher research and development costs, the price is even more expensive, even as high as hundreds of thousands of yuan. In comparison, generic drugs are more affordable. Lao generic drugs are one of the relatively low-priced generic drugs, with prices ranging from 2,000 yuan to 4,000 yuan. Compared with original drugs, they are more affordable. The ingredients of original drugs and generic drugs are basically the same.